Search

Galectin Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

3.41 -2.57

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.18

Max

3.54

Galvenie mērījumi

By Trading Economics

Ienākumi

454K

-5M

EPS

-0.08

Darbinieki

9

EBITDA

474K

-3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+211.61% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 14. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

169M

315M

Iepriekšējā atvēršanas cena

5.98

Iepriekšējā slēgšanas cena

3.41

Ziņu noskaņojums

By Acuity

40%

60%

134 / 340 Rangs Healthcare

Galectin Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. aug. 20:02 UTC

Galectin Therapeutics Inc shares are higher during Thursday's session, reflecting strong trading activity and unusually high market volume, despite lacking specific company news.

2026. g. 12. aug. 19:42 UTC

Galectin Therapeutics Inc shares are rising Wednesday amid high trading volume, maintaining an upward trend since Tuesday's close despite pulling back from earlier session highs.

2026. g. 11. aug. 19:56 UTC

Galectin Therapeutics Inc shares are lower today amid routine fluctuations and no specific news. The stock is near the lower end of its one-month trading range.

2026. g. 10. aug. 20:02 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a significant decline since Friday amid high trading volume and cautious investor sentiment following a weak jobs report.

2026. g. 8. aug. 00:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, reflecting strong buying activity. The stock has recovered from an early session low.

2026. g. 7. aug. 23:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, recovering from earlier losses amid favorable broader market conditions and a declining unemployment rate.

2026. g. 6. aug. 22:06 UTC

Galectin Therapeutics Inc shares are lower in after-market trading, continuing a trend below their 20-day moving average amid a significant decline since last month.

2026. g. 5. aug. 23:02 UTC

Galectin Therapeutics Inc shares are higher in after-market trading, despite no specific news driving the movement. The stock showed significant volatility during the session.

2026. g. 4. aug. 20:03 UTC

News

Galectin Therapeutics announced a $105.8 million debt-to-equity conversion but shares are lower today after an early peak. Trading volume is unusually high.

2026. g. 3. aug. 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

2026. g. 31. jūl. 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

2026. g. 30. jūl. 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

2026. g. 29. jūl. 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

2026. g. 28. jūl. 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

2026. g. 27. jūl. 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

2026. g. 24. jūl. 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

2026. g. 22. jūl. 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

2026. g. 21. jūl. 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

2026. g. 20. jūl. 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Salīdzinājums

Cenas izmaiņa

Galectin Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

211.61% augšup

Prognoze 12 mēnešiem

Vidējais 11 USD  211.61%

Augstākais 11 USD

Zemākais 11 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Galectin Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

134 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
help-icon Live chat